These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept. Forooghian F; Albiani DA; Kirker AW; Merkur AB Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR; JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850 [TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915 [TBL] [Abstract][Full Text] [Related]
30. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794 [TBL] [Abstract][Full Text] [Related]
31. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists. Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110 [TBL] [Abstract][Full Text] [Related]
32. Controlled and Extended In Vitro Release of Bioactive Anti-Vascular Endothelial Growth Factors from a Microsphere-Hydrogel Drug Delivery System. Osswald CR; Kang-Mieler JJ Curr Eye Res; 2016 Sep; 41(9):1216-22. PubMed ID: 26764892 [TBL] [Abstract][Full Text] [Related]
33. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO. Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721 [TBL] [Abstract][Full Text] [Related]
34. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept. Baisiwala S; Bundorf MK; Pershing S Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285 [TBL] [Abstract][Full Text] [Related]
35. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions. Hanhart J; Rozenman Y Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531 [TBL] [Abstract][Full Text] [Related]
36. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442 [TBL] [Abstract][Full Text] [Related]
37. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961 [TBL] [Abstract][Full Text] [Related]
38. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB. Bavinger JC; Yu Y; VanderBeek BL Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260 [TBL] [Abstract][Full Text] [Related]
39. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
40. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists. Singh N; Chang JS; Rachitskaya AV Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]